Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
1. Akari Therapeutics will participate in a virtual investor event on Sept 4. 2. CEO Abizer Gaslightwala will discuss the company's innovative ADC pipeline. 3. AKTX-101, Akari's lead drug, shows promise in preclinical studies. 4. The novel PH1 payload may enhance cancer treatment effectiveness. 5. Webcast replay available for 90 days post-event.